Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Akarna Therapeutics

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    Roche to acquire 89bio in a deal worth up to US$3.5bn

    With the agreement, Roche will gain a treatment for moderate to severe MASH

    - PMLiVE

    Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

    An estimated 1.2 million people in the US are currently living with the virus

    - PMLiVE

    Gilead Sciences and Kymera enter oncology partnership worth up to $750m

    The companies will focus on advancing Kymera’s oral molecular glue degrader programme

    - PMLiVE

    Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

    More than 100 people in the US were diagnosed with HIV every day in 2023

    - PMLiVE

    GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

    Steatotic liver disease affects approximately 5% of the global population

    - PMLiVE

    Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

    The drug has already been approved in the US to treat patients with non-cirrhotic MASH

    - PMLiVE

    Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

    The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

    - PMLiVE

    Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

    Primary biliary cholangitis affects approximately 163,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

    The company gained access to the drug through its $4.3bn acquisition of CymaBay

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    Gilead appoints Dietmar Berger as chief medical officer

    Berger most recently served as chief medical officer and global head of development at Sanofi

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links